Asleh K, Negri GL, Spencer Miko SE, et al. Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes. Nat Commun. 2022;13(1):896. Published 2022 Feb 16. doi:10.1038/s41467-022-28524-0

Raquib AR, Hofvander J, Ta M, Nielsen TO. Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma. Appl Immunohistochem Mol Morphol. 2022;30(8):531-539. doi:10.1097/PAI.0000000000001049

Klaric KA, Riaz N, Asleh K, et al. SRY-box transcription factor 10 is a highly specific biomarker of basal-like breast cancer. Histopathology. 2022;80(3):589-597. doi:10.1111/his.14592

Shenasa E, Stovgaard ES, Jensen MB, et al. Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial. Cancers (Basel). 2022;14(15):3808. Published 2022 Aug 5. doi:10.3390/cancers14153808

Ji JX, Cochrane DR, Negri GL, et al. The proteome of clear cell ovarian carcinoma [published online ahead of print, 2022 Aug 28]. J Pathol. 2022;10.1002/path.6006. doi:10.1002/path.6006

Huvila J, Cochrane DR, Ta M, et al. STING pathway expression in low-grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?. J Pathol Clin Res. 2021;7(6):548-555. doi:10.1002/cjp2.230

Lefort S, El-Naggar A, Tan S, et al. De novo and cell line models of human mammary cell transformation reveal an essential role for Yb-1 in multiple stages of human breast cancer. Cell Death Differ. 2022;29(1):54-64. doi:10.1038/s41418-021-00836-6

Zhang HF, Hughes CS, Li W, et al. Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma. Cancer Discov. 2021;11(11):2884-2903. doi:10.1158/2159-8290.CD-20-1690

Dixon K, Brew T, Farnell D, et al. Modelling hereditary diffuse gastric cancer initiation using transgenic mouse-derived gastric organoids and single-cell sequencing. J Pathol. 2021;254(3):254-264. doi:10.1002/path.5675